Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Autologous cell therapy industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Therapy trends
2.1.4 Source trends
2.1.5 Application trends
2.1.6 End-use trends
Chapter 3 Autologous Cell Therapy Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advancements in cell manufacturing technologies
3.2.1.2 Rising prevalence of chronic disease
3.2.1.3 Growing demand for personalized therapies
3.2.1.4 Increasing R&D activities undertaken by companies for autologous cell therapy
3.2.2 Industry pitfalls & challenges
3.2.2.1 Systemic immunological reactions
3.2.2.2 High cost of autologous cell therapy
3.3 Growth potential analysis
3.3.1 By therapy
3.3.2 By source
3.3.3 By application
3.3.4 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6 Technological landscape
3.7 Future potential
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategy outlook matrix
Chapter 5 Autologous Cell Therapy Market Size and Forecast, By Therapy (USD Million)
5.1 Key trends, by therapy
5.2 Autologous Cellular Immunotherapies
5.3 Autologous Stem Cell Therapy
Chapter 6 Autologous Cell Therapy Market Size and Forecast, By Source (USD Million)
6.1 Key trends, by source
6.2 Bone Marrow
6.3 Epidermis
6.4 Mesenchymal Stem Cells
6.5 Other sources
Chapter 7 Autologous Cell Therapy Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Cancer
7.3 Cardiovascular Disorders
7.4 Neurodegenerative Disorders
7.5 Orthopedics
7.6 Other applications
Chapter 8 Autologous Cell Therapy Market Size and Forecast, By End-use (USD Million)
8.1 Key trends, by end-use
8.2 Hospitals & Clinics
8.3 Ambulatory Surgical Centers
8.4 Research Centers
8.5 Other end-users
Chapter 9 Autologous Cell Therapy Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of MEA
Chapter 10 Company Profiles
10.1 BrainStorm Cell Therapeutics, Inc.
10.2 Holostem Terapie Avanzate S.r.l.
10.3 Lisata Therapeutics
10.4 Lonza Group AG
10.5 Opexa Therapeutics, Inc.
10.6 Novartis AG
10.7 Tegoscience
10.8 Autolus Therapeutics
10.9 Bristol-Myers Squibb Company
10.10 Corning Incorporated
10.11 Bio Elpida.
10.12 Vericel Corporation
10.13 Catalent, Inc.
10.14 Sartorius AG
